Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Share-based Compensation (2019 - 2025)

Historic Share-based Compensation for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $9.1 million.

  • Nurix Therapeutics' Share-based Compensation rose 679.36% to $9.1 million in Q4 2025 from the same period last year, while for Nov 2025 it was $38.0 million, marking a year-over-year increase of 1189.54%. This contributed to the annual value of $38.0 million for FY2025, which is 1189.54% up from last year.
  • Per Nurix Therapeutics' latest filing, its Share-based Compensation stood at $9.1 million for Q4 2025, which was up 679.36% from $9.8 million recorded in Q3 2025.
  • Nurix Therapeutics' Share-based Compensation's 5-year high stood at $10.4 million during Q2 2025, with a 5-year trough of $2.7 million in Q1 2021.
  • Its 5-year average for Share-based Compensation is $7.5 million, with a median of $8.4 million in 2022.
  • As far as peak fluctuations go, Nurix Therapeutics' Share-based Compensation skyrocketed by 143409.09% in 2021, and later crashed by 777.03% in 2024.
  • Nurix Therapeutics' Share-based Compensation (Quarter) stood at $4.8 million in 2021, then skyrocketed by 71.32% to $8.3 million in 2022, then fell by 3.29% to $8.0 million in 2023, then increased by 6.03% to $8.5 million in 2024, then increased by 6.79% to $9.1 million in 2025.
  • Its Share-based Compensation was $9.1 million in Q4 2025, compared to $9.8 million in Q3 2025 and $10.4 million in Q2 2025.